BBHC
AKBA icon

Brown Brothers Harriman & Co’s Akebia Therapeutics AKBA Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-113
Closed -$2K – 801
2017
Q4 		$2K Buy
+113
New +$1.87K ﹤0.01% 1013
2017
Q1 		– Sell
-318
Closed -$3K – 794
2016
Q4 		$3K Hold
318
– – ﹤0.01% 810
2016
Q3 		$3K Sell
318
-2,000
-86% -$17K ﹤0.01% 725
2016
Q2 		$17K Buy
+2,318
New +$20.2K ﹤0.01% 569

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Brown Brothers Harriman & Co's AKBA Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of Akebia Therapeutics (AKBA) in Q1 2018, closing a stake of 113 shares — an estimated $2K sold.

Brown Brothers Harriman & Co first reported a position in AKBA in Q2 2016 and held it in 4 quarters. The position peaked at $17K in Q2 2016. 153 funds tracked by Wall St. Rank hold AKBA as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining Akebia Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 113 Akebia Therapeutics shares in Q1 2018, an estimated $2K.
  • Brown Brothers Harriman & Co first reported a position in Akebia Therapeutics in Q2 2016 and held it in 4 quarters.
  • Brown Brothers Harriman & Co's Akebia Therapeutics position peaked at $17K in Q2 2016.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.